All In Biotech

Drug Trial Radar · NCT06395194

Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension

The Valsartan Antihypertensive Long-term Use Evaluation Trial

Last checked: Nov 19, 2026Latest source record: May 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 15,313 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

15,313

Actual

Start

Sep 27, 1997

Primary completion

Sep 5, 2003

Study completion Dec 5, 2003

Sponsor

Lead sponsor
Oslo University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Oslo
First posted
May 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial tested the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. The present study investigates effects of valsartan and amlodipine on pre-specified secondary kidney outcomes.

Conditions

  • Essential Hypertension

Interventions

  • Cardiac outcomes on treatment with valsartanDrug

    Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase ("rolled over"). Valsartan treatment started at a dosage of 80 mg daily. If BP did not reach \<140/90 mmHg, the valsartan dose was doubled to 160 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.

  • Cardiac outcomes on treatment with amlodipineDrug

    Patients who already were on treatment, discontinued their previous antihypertensive medications when randomized to one of the trial's masked study arms (valsartan or amlodipine) without a run-in phase ("rolled over"). Amlodipine treatment started at 5 mg daily. If BP did not reach \<140/90 mmHg, the amlodipine dose was doubled to 10 mg, and then hydrochlorothiazide (12.5 mg and 25 mg daily) and other antihypertensive drugs were added in sequential steps.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite cardiac event (mostly myocardial infarction and heart failure hospitalization)Time frame: Up to 6 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.